Suppr超能文献

胰头癌行腹腔动脉干切除的胰体尾切除术的预后:一项泛欧回顾性队列研究。

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study.

机构信息

Department of Surgery, Cancer Center Amsterdam, Academic Medical Center, Amsterdam, the Netherlands.

Department of Digestive Surgery, E. Herriot Hospital, HCL, UCBL1, Lyon, France.

出版信息

Ann Surg Oncol. 2018 May;25(5):1440-1447. doi: 10.1245/s10434-018-6391-z. Epub 2018 Mar 12.

Abstract

BACKGROUND

Western multicenter studies on distal pancreatectomy with celiac axis resection (DP-CAR), also known as the Appleby procedure, for locally advanced pancreatic cancer are lacking. We aimed to study overall survival, morbidity, mortality and the impact of preoperative hepatic artery embolization (PHAE).

METHODS

Retrospective cohort study within the European-African Hepato-Pancreato-Biliary-Association, on DP-CAR between 1-1-2000 and 6-1-2016. Primary endpoint was overall survival. Secondary endpoints were radicality (R0-resection), 90-day mortality, major morbidity, and pancreatic fistulae (grade B/C).

RESULTS

We included 68 patients from 20 hospitals in 12 countries. Postoperatively, 53% of patients had R0-resection, 25% major morbidity, 21% an ISGPS grade B/C pancreatic fistula, and 16% mortality. In total, 82% received (neo-)adjuvant chemotherapy and median overall survival in 62 patients with pancreatic ductal adenocarcinoma patients was 18 months (CI 10-37). We observed no impact of PHAE on ischemic complications.

CONCLUSIONS

DP-CAR combined with chemotherapy for locally advanced pancreatic cancer is associated with acceptable overall survival. The 90-day mortality is too high and should be reduced. Future studies should investigate to what extent increasing surgical volume or better patient selection can improve outcomes.

摘要

背景

西方多中心研究表明,对于局部进展期胰腺癌,行腹腔动脉干切除的胰体尾切除术(DP-CAR),也称为 Appleby 手术,术后总体生存率、发病率、死亡率以及术前肝动脉栓塞术(PHAE)的影响尚不清楚。

方法

在欧洲-非洲肝胆胰协会内进行回顾性队列研究,纳入 2000 年 1 月 1 日至 2016 年 1 月 6 日期间行 DP-CAR 的患者。主要终点为总体生存率。次要终点为根治性(R0 切除)、90 天死亡率、主要发病率和胰瘘(B/C 级)。

结果

共纳入来自 12 个国家 20 家医院的 68 例患者。术后,53%的患者达到 R0 切除,25%的患者发生主要并发症,21%的患者发生 ISGPS 分级 B/C 级胰瘘,16%的患者死亡。共有 82%的患者接受了(新)辅助化疗,62 例胰腺导管腺癌患者的中位总生存时间为 18 个月(95%CI 10-37)。我们观察到 PHAE 对缺血性并发症无影响。

结论

DP-CAR 联合化疗治疗局部进展期胰腺癌总体生存率可接受。90 天死亡率过高,需要降低。未来的研究应探讨增加手术量或更好的患者选择在多大程度上可以改善预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/814f/5891548/7860ede94033/10434_2018_6391_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验